Estimated Time to Complete Educational Activity
In this web-based program, physicians will learn how recent developments in multimodal therapies have advanced the management of high cholesterol levels in diabetic patients.
August 30, 2018
August 30, 2020
Method of Physician Participation Utilized in Learning Process
There are no fees for participating and receiving CME credit for this activity. During the period August 30, 2018 through August 30, 2020 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 6 segments totaling 2.5 hours to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.
Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.
Supported by an educational grant from Sanofi US and Regeneron Pharmaceuticals
This activity has been planned and implemented in accordance with accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Postgraduate Institute for Medicine and CMEducation Resources, LLC. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Policy on Faculty & Provider Disclosure
It is the policy of the Postgraduate Institute for Medicine to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the Postgraduate Institute for Medicine are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCM.
Program Faculty and Disclosure
Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC - Program Chair
Interventional Cardiovascular Programs
Brigham and Women’s Hospital
Heart and Vascular Center
Professor of Medicine
Harvard Medical School
Contracted Research: Abbott, Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis, The Medicines Company
Lawrence A. Leiter, MD
Head, Division of Endocrinology and Metabolism
Director, Lipid Clinic
Associate Director, Clinical Nutrition and Risk Factor Modification Centre
St. Michael’s Hospital
Professor of Medicine and Nutritional Sciences
University of Toronto
Toronto, Ontario, Canada
Consultant: AstraZeneca, Amgen, Merck, Sanofi/Regeneron
Speaker: AstraZeneca, Amgen, Esperion, Kowa, Merck, Sanofi/Regeneron, the Medicines Company
James M. McKenney, PharmD
President and Chief Executive Officer
National Clinical Research, Inc.
Virginia Commonwealth University School of Medicine
Dr. McKenney is an employee of National Clinical Research which has received funding for lipid modifying research from Sanofi, Regeneron, Esperion, Amgen, and The Medicines Company
Upon completion of this activity, participants will be able to:
- Outline the mechanisms of agents that reduce LDL levels, CV outcomes-based trials, and translational implications of employing non-statin-based therapies—including PCSK9 inhibitors—to reduce ASHD risk in patients across the diabetes CV risk spectrum
- Evaluate evidence-based treatment options—in particular, those supported by CV outcomes-based landmark trials—in diabetic patients who are intolerant to statins, unable to achieve desired LDL targets, or unable to take statins, and who require additional LDL lowering to optimize CV risk reduction
- Summarize the recently issued Year 2017 ACC/ECDP (Expert Consensus Decision Pathway) Recommendations for non-statin-based therapeutic interventions, including those mediated by PCSK9 inhibitors, for diabetic patients at risk for primary and secondary prevention of ASHD
- Detail the epidemiology, disease burden, scientific knowledge base, and landmark trials that explain the central importance of cardiovascular risk reduction in the diabetic population
- Apply the results, conclusions, safety data, LDL-lowering efficacy, dosing strategies, and patient monitoring aspects of patients treated with PCSK9 inhibitors in major CV outcomes-focused clinical trials evaluating the effect of these agents on MI, non-fatal MI, stroke, CV-related mortality and other end points
Hardware and Software Requirements:
To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.
When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:
- We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
- For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
- We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
- If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.